Optimisation Of Wolbachia Based Control Strategies To Reduce Dengue Incidence And Disease
Funder
National Health and Medical Research Council
Funding Amount
$6,073,640.00
Summary
The project will build on recent advances in the use of Wolbachia infected mosquitoes to limit dengue transmission. Key outcomes will include improved understanding of Wolbachia spread after release, development of techniques for regional spread, understanding the epidemiology of dengue transmission in Vietnam and preparing a panel of new Wolbachia:A. aegypti strain combinations for evaluation for implementation programs.
The Australian MRI-Linac Program: Transforming The Science And Clinical Practice Of Cancer Radiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$7,001,475.00
Summary
Radiotherapy is indicated for 48% of cancer patients. The Australian MRI-Linac Program will change the science and clinical practice of radiotherapy by explicitly targeting the dynamic anatomy and physiology of cancer, increasing cancer control and decreasing treatment side effects. Successful completion of this program will have a direct impact on the treatment and lives of Australian cancer patients in the foreseeable future.
Dengue, Zika and Chikungunya are viral diseases transmitted to humans by mosquitoes. Our research uses a naturally-occurring bacteria, Wolbachia, to stop mosquitoes transmitting these viruses to humans. Our proposal addresses critical knowledge gaps in the biology of mosquitoes and Wolbachia to enable large-scale field-deployment optimisation in affected countries. The outcome of our research will immediately translate to disease control efforts in northern Australia, Asia and Latin America.
Improving Stroke Outcomes: Attenuating Progression And Recurrence
Funder
National Health and Medical Research Council
Funding Amount
$9,331,996.00
Summary
Stroke is the second most common cause of death and major cause disability. There are few proven interventions, so we need to introduce new ones. We developed a bench to bedside program to introduce new stroke therapies and its early secondary prevention. Our general goal is to provide evidence for their effectiveness and safety. We will use animal stroke models, markers in the blood to help diagnose and predict stroke outcome and imaging to help select patients for several clinical trials.